8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 18, 2019

 

 

Apellis Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

 

 

Delaware   001-38276   27-1537290

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

6400 Westwind Way, Suite A

Crestwood, KY

  40014
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (502) 241-4114

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock   APLS   Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 


Item 5.07. Submission of Matters to a Vote of Security Holders.

Apellis Pharmaceuticals, Inc. (the “Company”) held its Annual Meeting of Stockholders on June 18, 2019. The following is a summary of the matters voted on at that meeting.

 

  (a)

The stockholders of the Company elected A. Sinclair Dunlop and Alec Machiels as class II directors, each for a three-year term ending at the annual meeting of stockholders to be held in 2022. The results of the stockholders’ vote with respect to the election of the class II directors were as follows:

 

Name

  

For

  

Withheld

  

Broker Non-Votes

A. Sinclair Dunlop

   39,310,059    4,574,084    6,243,488

Alec Machiels

   39,371,580    4,512,563    6,243,488

 

  (b)

The stockholders of the Company ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2019. The results of the stockholders’ vote with respect to such ratification were as follows:

 

For

  

Against

  

Abstain

  

Broker Non-Votes

50,000,793

   283    126,555   

 

  (c)

The stockholders of the Company approved the advisory vote on the compensation of the Company’s named executive officers. The results of the stockholders’ vote with respect to the advisory proposal were as follows:

 

For

  

Against

  

Abstain

  

Broker Non-Votes

43,532,878

   223,031    128,233    6,243,489

 

  (d)

The stockholders of the Company held an advisory vote on the frequency of future executive compensation advisory votes. The results of the stockholders’ vote with respect to the advisory proposal were as follows:

 

Every 1 Year

  

Every 2 Years

  

Every 3 Years

  

Abstain

  

Broker Non-Votes

41,583,274

   2,801    49,342    2,248,725    6,243,489

After taking into consideration the foregoing voting results and the prior recommendation of the Company’s Board of Directors in favor of an annual advisory stockholder vote on the compensation of the Company’s named executive officers, the Board of Directors intends to hold future executive compensation advisory votes every year.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Apellis Pharmaceuticals, Inc.

Date: June 21, 2019

 

By:

 

/s/ Cedric Francois

   

Cedric Francois, M.D., Ph.D.

   

President and Chief Executive Officer